News >

Biosimilar Rituximab Approved in Europe for Non-Hodgkin Lymphoma

Jason Harris
Published: Monday, Jun 19, 2017

Carol Lynch

Carol Lynch
The European Commission (EC) has approved the rituximab (Rituxan) biosimilar Rixathon (GP2013) to treat patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

Today’s EU approval for Rixathon also includes indications for immunological diseases, such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiiti.
Jurczak W, Ilidia M, Govindbabu KS, et al. A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in patients with previously untreated advanced follicular lymphoma. Presented at: 58th American Society of Hematology Annual Meeting; San Diego, CA; December 3-6, 2016. Abstract 1151.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication
x